[4]DUPLOYEZ N, WILLEKENS C, MARCEAU-RENAUT A, et al. 2015. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert Rev Hematol [J], 8: 43-56. [5]DOHNER H, ESTEY E, GRIMWADE ...
【翻译】这一疾病进展为急性髓系白血病似乎有接近100%的外显率,但患病率尚不清楚。 Both monoallelic and biallelic mutations occur in sporadic AML, but only biallelic mutations are associated with a good prognosis. 【翻译】单等位和双等位(CEBP...
D. Anderson, USA, suggested that AML children 100×109/L 18 (17%) 14 (9%) 18 (14%) p = 0.10 Cytogenetics t(8;21) t(9;11) Other MLL 1 (1%) 14 (13%) 21 (19%) 24 (15%) 12 (7%) 16 (10%) 15 (12%) 9 (7%) 9 (7%) p = 0.01 p = 0.39 p = 0.03 FAB type ...
In general, AML prognosis is broadly stratified based on patient age. Patients 60 years old or younger have a 35–40 % chance of achieving a cure while those older than 60 have only a 5–15 % chance [2]. Yet, AML prevalence is much more common among the elderly with a median age ...
Prognosis of acute myeloid leukemia (AML) patients depends on patient-related features, disease manifestations at the time of presentation, and intrinsic disease-related genetic features, such as cytogenetic abnormalities and driver mutations. Prognostic stratification also depends on the therapeutic strategy...
Your doctor will do a staging workup after your diagnosis, which will give them a better idea of your prognosis based on your specific medical situation.
(Cheng et al.2023). Patients who do not acheive CR after this regimen have a poor prognosis, with factors such as leukocytosis, older age, and high-risk cytogenetics contributing to induction failure (Ho and Becker2013). Approximately 10–40% of newly diagnosed AML patients do not achieve ...
HCT is never indicated in patients in CR1, except for the small fraction of patients with per- sistent RQ-PCR positivity of PML-RARA after consolidation (<1%), given the poor prognosis associated with this subset. HCT is also indicated in APL patients who relapse and achieve second or ...
Additionally, the fairly good sensitivity, specificity, and clinical relevance of miR-182 promoter methylation discovered in our study make it a valuable tool for identifying and monitoring methylation changes associated with prognosis. Therefore, we offer a rapid and quantitative method to predict the ...
prognosis [8,9]. Thus, risk stratification ofNPM1-mutated AML is an evolving area that in the future is expected to expand, including genotypes other than those currently recognized by the ELN. A recent study also points to the importance of race in risk stratification based on genomics [10...